

# LDG GmbH Honored with Global 100 - 2025 Award for Excellence in Biotechnology and Life Sciences

ULM, GERMANY, March 31, 2025 /EINPresswire.com/ -- LDG GmbH (Laboratories Dr. Gansauge), a global leader in advanced cancer immunotherapy, has been awarded the prestigious Global 100 - 2025 Award in the Biotechnology / Life Sciences category. This international recognition highlights LDG's cutting-edge contributions to the development of dendritic cell-based therapies—a revolutionary approach in the fight against cancer.

Pioneering Innovation in Cancer Treatment



Dr. Frank Gansauge

Founded by Dr. Frank Gansauge, LDG GmbH has emerged as a trailblazer in the field of personalized cancer immunotherapy, with a focus on LANEX-DC<sup>®</sup>, their proprietary dendritic cell vaccine. Unlike conventional cancer treatments, LDG's immunotherapy activates the patient's

own immune system, training it to identify and destroy cancer cells while preserving healthy tissue. This targeted approach represents a major breakthrough for patients with limited treatment options.

“

This recognition reflects our team's unwavering dedication to advancing Our mission is to empower the immune system to fight cancer naturally and effectively.”

*Dr. Frank Gansauge*

To date, more than 3,500 patients have received LANEX-DC<sup>®</sup> therapy, with notable success in treating challenging cancers such as melanoma, kidney, pancreatic, prostate, breast, ovarian, and colorectal cancers. LDG's ongoing research continues to improve outcomes and extend survival rates for patients worldwide.

## Commitment to Science and Patient-Centered Care

The Global 100 award underscores LDG's dual commitment to scientific innovation and compassionate patient care. LDG's therapies are designed around the individual, ensuring that each treatment is tailored to the unique biological profile of the patient's cancer. This personalized model leads to more effective responses with fewer side effects, providing patients with improved quality of life during treatment.

LDG's state-of-the-art laboratories are equipped with cutting-edge cell culture and immune monitoring technologies, enabling their scientific team to maintain the highest standards of quality and safety. In addition, LDG collaborates with leading research institutions and clinicians worldwide to continually refine its methods and contribute to the broader field of cancer immunotherapy research.

## A Global Leader in Dendritic Cell Immunotherapy

With over 7,000 scientific studies supporting the field of dendritic cell therapy globally, LDG GmbH has positioned itself as a front-runner in translating this research into real-world clinical application. Their proprietary LANEX-DC® process has been meticulously developed and validated to meet the needs of patients at all stages of cancer progression, including those for whom standard therapies have failed.

Dr. Frank Gansauge, Founder and Chief Scientist of LDG GmbH, commented on the award:

"We are honored to receive the Global 100 Award. This recognition reflects our team's unwavering dedication to advancing science and offering hope to patients facing difficult diagnoses. Our mission is to empower the immune system to fight cancer naturally and effectively. This award is a testament to the lives we have impacted and the future we aim to build."

## Shaping the Future of Cancer Care



Looking ahead, LDG GmbH is focused on expanding global access to dendritic cell immunotherapy, forging international collaborations to bring LANEX-DC® to more patients. The company is also investing in next-generation research, combining dendritic cell vaccines with other emerging immunotherapies to further improve patient outcomes.

By remaining at the forefront of personalized medicine, LDG aims to redefine the standard of cancer care, shifting from one-size-fits-all approaches to targeted, immune-driven treatments that work in harmony with the body's natural defenses.

About LDG GmbH (Laboratories Dr. Gansauge)

Based in Ulm and Berg Germany, LDG GmbH specializes in personalized dendritic cell-based immunotherapy for cancer patients. With a deep commitment to scientific excellence and individualized care, LDG is a global leader in the fight against cancer, offering hope through innovative, patient-specific therapies.

For more information, please visit [www.labor-gansauge.de](http://www.labor-gansauge.de)

Dr. Frank Gansauge

LDG - Laboratories Dr. Gansauge GmbH

info@labor-gansauge.de

---

This press release can be viewed online at: <https://www.einpresswire.com/article/798776803>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.